Abstract
Heterogeneity of lung tumor endothelial cell (TEC) phenotypes across patients, species (human/mouse), and models (in vivo/in vitro) remains poorly inventoried at the single-cell level. We single-cell RNA (scRNA)-sequenced 56,771 endothelial cells from human/mouse (peri)-tumoral lung and cultured human lung TECs, and detected 17 known and 16 previously unrecognized phenotypes, including TECs putatively regulating immune surveillance. We resolved the canonical tip TECs into a known migratory tip and a putative basement-membrane remodeling breach phenotype. Tip TEC signatures correlated with patient survival, and tip/breach TECs were most sensitive to vascular endothelial growth factor blockade. Only tip TECs were congruent across species/models and shared conserved markers. Integrated analysis of the scRNA-sequenced data with orthogonal multi-omics and meta-analysis data across different human tumors, validated by functional analysis, identified collagen modification as a candidate angiogenic pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 21-36.e13 |
Journal | Cancer Cell |
Volume | 37 |
Issue number | 1 |
DOIs | |
State | Published - Jan 13 2020 |
Bibliographical note
Funding Information:We acknowledge K. Peeters, T. Van Brussel, and R. Schepers for assistance. J.G., K.R., L.T., and J.K. are supported by the ‘ Fonds Wetenschappelijk Onderzoek ’ (FWO); L.-C.C. by the Else Kröner-Fresenius and Fritz Thyssen Stiftung (10.16.2.017MN); A.P. by the Austrian Science Fund ( J3730-B26 ); L.-A.T. by Antwerp University ; V.G. by Strategisch Basisonderzoek FWO (SB-FWO); S.K. by Kom op Tegen Kanker (Stand up to Cancer, Flemish Cancer Society ); M.M. by Methusalem funding ( Flemish Government ); L.B. and Y.L. by Sanming Project of Medicine in Shenzhen ( SZSM201612074 ); L.L. by Lundbeck Foundation ( R219–2016-1375 ) and DFF Sapere Aude Starting grant ( 8048-00072A ); Y.L. by BGI -Research, Danish Research Council for Independent Research ( DFF–1337–00128 ), Sapere Aude Young Research Talent Prize ( DFF-1335–00763A ), and Aarhus University Strategic Grant (AU-iCRISPR); X.L. by State Key Laboratory of Ophthalmology , Zhongshan Ophthalmic Center ( Sun Yat-sen University ) and National Natural Science Foundation of China ( 81670855 ), Key Program of Guangzhou Scientific Research Plan ( 3030901006074 ); and P.C. by VIB TechWatch , Methusalem funding, FWO, Foundation against Cancer ( 2016-078 ), Kom op tegen Kanker (Stand up to Cancer, Flemish Cancer Society), ERC Proof of Concept ( ERC-713758 ), and Advanced ERC Research Grant ( EU-ERC743074 ).
Funding Information:
We acknowledge K. Peeters, T. Van Brussel, and R. Schepers for assistance. J.G. K.R. L.T. and J.K. are supported by the ‘Fonds Wetenschappelijk Onderzoek’ (FWO); L.-C.C. by the Else Kröner-Fresenius and Fritz Thyssen Stiftung (10.16.2.017MN); A.P. by the Austrian Science Fund (J3730-B26); L.-A.T. by Antwerp University; V.G. by Strategisch Basisonderzoek FWO (SB-FWO); S.K. by Kom op Tegen Kanker (Stand up to Cancer, Flemish Cancer Society); M.M. by Methusalem funding (Flemish Government); L.B. and Y.L. by Sanming Project of Medicine in Shenzhen (SZSM201612074); L.L. by Lundbeck Foundation (R219–2016-1375) and DFF Sapere Aude Starting grant (8048-00072A); Y.L. by BGI-Research, Danish Research Council for Independent Research (DFF–1337–00128), Sapere Aude Young Research Talent Prize (DFF-1335–00763A), and Aarhus University Strategic Grant (AU-iCRISPR); X.L. by State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center (Sun Yat-sen University) and National Natural Science Foundation of China (81670855), Key Program of Guangzhou Scientific Research Plan (3030901006074); and P.C. by VIB TechWatch, Methusalem funding, FWO, Foundation against Cancer (2016-078), Kom op tegen Kanker (Stand up to Cancer, Flemish Cancer Society), ERC Proof of Concept (ERC-713758), and Advanced ERC Research Grant (EU-ERC743074). J.G. K.R. F.T. and L.T. designed and analyzed experiments. J.G. L.T. L.-C.C. A.P. J.K. and M.G-C. set up the EC isolation protocols. L.-C.C. E.W. H.D, P.DL. J.V. B.W. X.S. E.V. A.W. B. Topal, W.E. H.B. and A.E. provided human tumor samples. K.R. L.T. L.-C.C. V.G. J.K. L. Sokol, J.Q, and L.-A.T. prepared the scRNA-seq samples. L.L. B. Thienpont, D.L. and Y.L. did 10× single-cell sequencing. S.K. B.B. and T.K. processed scRNA-seq data. L.dR. J.K. D.P. F.D.S. F.J.T.S. R.J.M. and Y.Z. did CyTOF. L.T. J.K. and S.V. did immunohistochemistry. F.I. did proteomics analysis. V.L. provided advice on the statistical methodology. F.D.S. M.M. G.E. M.D. L. Schoonjans, H.Y. J.W. L.B. L.L. B. Thienpont, X.L. D.L. and Y.L. provided advice and discussed the results. J.G. K.R. and P.C. wrote the manuscript. P.C. conceptualized the study. All authors discussed the results and the manuscript. The authors declare no competing interests.
Publisher Copyright:
© 2019 Elsevier Inc.
Keywords
- angiogenesis
- anti-angiogenic therapy
- cancer
- endothelial cells
- endothelial heterogeneity
- multi-omics
- single-cell RNA sequencing
ASJC Scopus subject areas
- Oncology
- Cancer Research